

DAFTAR PUSTAKA

- Acs, G., Lawton, T.J., Rebbeck TR., Livolsi, VA., Zhang PJ. 2001. Differential Expression of E-Cadherin in Lobular and Ductal Neoplasms of the Breast and its Biologic and Diagnostic Implication. *American Journal of Clinical Pathology*, 115(1):85-98.
- Andersen, H., Mejlvang, j., Mahmood, S., Gromova, I., Gromov, P., Lukanidin, E., Kriajevska, M., Mellon, JK., Tulchinsky, E. 2005. *Molecular and Cellular Biology*, 25(20):9138-9150.
- Angahar, L.T..2017. An Overview of Breast Cancer Epidemiology, Risk Factor, Pathophysiology, and Cancer Risk Reduction. *MOJ Biol Med*, 1(4):1-5.
- Alberkstein, G., Heuch, I., Thoresen, SO. 2010. Histological Type and Grade of Breast Tumor by Parity, Age at Birth, and Time since Birth:A Register-Based Study in Norway. *BMC Cancer*, 10(226):1-11.
- Almasri, N. dan Hamad, MA. 2005. Immunohistochemical Evaluation of Human Epidermal Growth Factor Receptor 2 and Estrogen and Progesterone Receptors i Breast Cancer Carcinoma in Jordan. *Breast Cancer Research*, 7(5): R598-R604.
- Arteaga, CL., Sliwkowski, MX., Osborne CK., Perez, EA. 2011. Treatment of HER2 Positif Breast Cancer: Current Status and Future Perspective. *Natural Review Clinical Oncology*, 9(1):16-32.
- Australian Government. 2015. *Breast Cancer in Young Women, Key Fact About Breast Cancer in Women 20s and 30s*. Canberra: Australian Institute Healthcare and Welfare.
- Berger, MS., Locher G.W., Saurer S., Gullicet WJ., Waterfiels MD., Goner B., Hynes, NE. 1988. Correlation of C-erb2 Gene Amplification and Protein Expression in Human Breast Carcinoma with Nodal Status and Nuclear Grading. *Cancer Res*, 18:1238-1243.
- Biswal, P., Behera, S., Kar, A., Pradhan, D., Behera, PK., Burma, S., Mishra, C. 2015. Correlation of Hormonal Receptors Estrogen Receptor, Progesterone Receptor, and Her-2/Neu with Tumor Characteristics in Breast Carcinoma: Study of 100 Consecutive Cases. *Internatinal Journal of Clinical Medicine*, 6(12): 961-966.
- Briskin, C.. 2013. Progesterone Signaling in Breast Cancer: a Neglected Hormone Coming into the Limelight. *Cancer*, 13(1): 358-396.
- Briskin, C., Hess, K., Jeitziner, R. 2015. Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. *Endocrinology*, 156(10):3442-34

- Collaborative Group on Hormonal Factors in Breast Cancer. 2012. Menarche, Menopause, and Breast Cancer Risk: Individual Participant Meta-analysis, Including 118 964 Women with Breast Cancer from 117 Epidemiological Studies. *The Lancet Oncology*, 13(11):1141-1151.
- Collin, LC., Botero, ML., Schnitt, SJ. 2005. Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Result in Breast Cancer., *American Journal of Clinical Pathology*, 123: 16-20.
- Cowell, CF., Weigelt, B., Sakr, RA., Ng, CK., Hicks, J., King, TA., Reis-Filho, JS. 2013. Progression from Ductal Carcinoma in situ to Invasive Breast Cancer: Revisited. *Molecular Oncology*, 7(5): 859-869.
- Daniel, A.R., Hagan, CR., Lange, CA. 2011. Progesterone Receptor Action: Defining a Role in Breast Cancer. *Expert Rev Endocrinol Metab*, 6(3): 359-369.
- DeSantis, CE., Ma, J., Goding, SA., Newman LA., Jemal, A. 2017. Breast Cancer Statistics, 2017, Racial Disparity in Mortality by State. *CA: Cancer Journal for Clinicians*, 67(6):439-448.
- Devi, PU. 2004. Basic of Carcinogenesis. *Health Administrator*, 17(1): 16-24.
- Dewi, GAT. dan Hendrati, LY. 2015. Analisis Risiko Kanker Payudara Berdasar Riwayat Pemakaian Kontrasepsi Hormonal dan Usia Menarche. *Jurnal Berkala Epidemiologi*. 3(1): 12-23.
- Dressing, GE., Hagan, CR., Knutson, TP., Daniel, AR., Lange, CA. 2009. Progesterone Receptor Act As Sensors for Mitogenic Protein Kinases in Breast Cancer Models. *Endocrine Related Cancer*, 16(2):351-361.
- Dressing, GE., Knutson, TP., Schiewer, MJ., Daniel, AR., Hagan, CR., Diep, CH., Knudson, KE., Lange, CA. 2014. Progesterone Receptor Cyclin D1 Complexes Induce Cell Cycle Dependent Transcriptional Program in Breast Cancer Cells. *Molecular Endocrinology*, 28(4):442-457.
- Fan, L., G., Paul E., W., Kathrin Strasser. 2015. Current Status and Future Projection of Breast Cancer in Asia. *Breast Care*, 10(1):372-378.
- Firdaus, VRP., Asri, A., Khambri, D., Harahap, WA. 2016. Hubungan Grading Histopatologi dan Infiltrasi Limfovaskular dengan Subtipe pada Kanker Payudara Invasif di Bagian Bedah RSUP. Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 5(1): 165-172.
- Gajria, D. dan Chandrapaty, S. 2011. HER2-amplified Breast Cancer: Mechanism of Trastuzumab Resistance and Novel Targeted Therapies. *Expert Rev Anticancer Therapy*, 11(2): 263-275.

- Gamallo, C., Palacios, J., Suarez, A., Pizarro A., Navarro, P., Quintanilla, M., Cano, A. 1993. Correlation of E-Cadherin Expression with Differentiated Grade and Histological Type in Breast Carcinoma. *American Journal of Pathology*, 142(4): 987-993.
- Gauss, JM., Yee, D. 2002. How Does the Esterogene Receptor Work?. *Breast Cancer Research* , 4:62.
- Gilbert, CA. dan Slingerland, JM. 2013. Cytokines, Obesity, and Cancer: New Insight on Mechanisms Linking Obesity to Cancer Risk and Progression. *Annual Review of Medicine*, 64(1): 45-57.
- Gloyeske, NC., Dabbs, DJ., Bhargava, R. 2014. Low ER Positve Breast Cancer, is this a Distinct Group?. *American Journal Clinical Phatology*, 141:697-701.
- Gupta, D., Gupta, V., Marwah, N., Gill, M., Gupta, S., Gupta, G., Jain, P., Sen, R. 2015. Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors. *Iranian Journal of Pathology*, 10(1):23-34.
- Hagan, CR.. 2014. Molecular Determinants of Context-dependent Progesteron Receptor Action in Breast Cancer. *BMC Medicine*, 12(32): 1-9.
- Hanif, MS., Busha, M., Amir, A., Akhtar, N., Farkhanda, H., Salman.2015. Breast Cancer:Incidence (Thirteen Year Data Analysis) and One Year Clinocopathological Data of Patients in a Tertiary Care Cancer Hospital. *International Journal Biotechnology*, 12(3):373-379.
- Hilton, HN., G., Graham, JD., Clarke, CL. 2015. Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: a Tale of Two Scenarios?. *Molecular Endocrinology*, 29(9):1230-1241.
- Hong, Y.L., Y., Li Ying, P. Xin Yan, F., Qiang, Z., Hong, S., Shu Ling, W., li, W., Peng, B., Shuang, Z., Xin Liang, Y., Ju Lun. 2016. Mutation Status of Ras Genes in Breast Cancer with Overexpressed p21Ras Protein. *Int J Exp Pathol* 9(10):10422-10429.
- Kaminska, M., Ciszewski, T., Lopacka-Szatan, K., Staroslawska, E. 2015. Breast Cancer Risk Factor. *Menopause Review Przegland Menopauzalny*, 14(3): 196-202.
- Kamil, M., Khalid, I., Hashim, H., Biswas, M., Kaur, G., Islam, R. 2010. Association of Carcinoma Breast:Grade and Estrogen Progesterone Receptor Expression. *Journal of the College of Physician and Surgeon Pakistan*, 20(4):250-252.
- Kariagina, A., Xie, J., Langohr, IM., Opreanu, RC., Basson, MD., Haslam, SZ. 2013. Progesterone Decreases Level of the Adhesion Protein E-cadherin and

- Promotes Invasiveness of Steroid Receptor Positive Breast Cancers. *Horm Cancer*, 4(6): 371-380.
- Kementerian Kesehatan. 2015. *Situasi Penyakit Kanker*. Pusat Data dan Informasi Kementerian Kesehatan RI, Jakarta. 44 hal.
- Khalis, M., C., Charbotel, B., Chajes, V., Rinaldi, S., Moskal, A., Biessy, C., Dossus, L., Huybrechts, I., *et al.* 2018. Menstrual and Reproductive Factors and Risk of Breast Cancer: A case-control Study in the Fez Region, Morocco. *Plos One*, 13(1): 1-12.
- Kim, Y., Yoo, KY., Goodman, MT. 2015. Difference in Incidence, Mortality and Survival of Breast Cancer by Regions and Countries in Asia and Contributing Factors. *Asian Pacific Journal of Cancer Prevention*, 16(1): 2857- 2870.
- Knutson, TP., Lange, CA. 2014. Tracking Progesterone Receptor Mediated Action in Breast Cancer. *Pharmacology Therapy*, 142(1):114-125.
- Kotepui, M.. 2016. Diet and Risk of Breast Cancer. *Contemporary Oncology (Poznan, Polland)*, 20(1): 13-19.
- Kumar, V., Cotran, RS., Robbin SL. 2015. *Buku Ajar Patologi Robbins, Edisi 9*. Elsevier: Singapura.
- Lakhani, SR., Ellis, IO., Schnitt, SJ., Tan, PH., Vijver, MJVD. 2012. *WHO Classification of Tumours of the Breast*. Switzerland: WHO Press
- Lingegowda, JB., Muddegowga, PH., Ramakantha, CK., Chandrasekar, HR. 2010. Cytohistology Correlation of Grading in Breast Carcinoma. *Diagn Cytopathol*, 39(4):251-257.
- Lopez-Tarruda, S. dan Schiff R.. 2007. The Dynamic of Receptor Status in Breast Cancer: Re Shaping the Paradigm. *Clinical Cancer Research*, 13(23):6921-6925.
- Makki, J. 2015. Diversity of Breast Cancer Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insight Pathology*, 8(1): 23-31.
- Medarde, A.F., &S. Eugenio. 2011. Ras in Cancer and Developmental Disease. *Genes and Cancer* 2(3):344-358.
- Mittal, A., Prasad, CSBR., PN S., D S., Khan N., Joshi, RU. 2017. Histopathological Grade Versus Estrogen and Progesteron Receptor Status in Carcinoma Breast – A Single Center Study. *Open Access J Surg* 4(3):1-4.
- Nagajaran, D., McArdle, SEB. 2018. Immune Landscape of Breast Cancer. *Biomedicine*, 6(20):1-12.
- Pajenga, E., Rexha, T., Celiku, S., Ugrinska, A., Bejta, G. 2016. Hormonal Receptor, Human Epidermal Growth Factor and its Association with Breast

- Cancer Tumor Characteristics in Albania. *Central European Journal Public Health*, 24(3):171-175.
- Pathak TB., Basyal, R., Pun, CB., Shresta, S., Bastola, S., Neupane, S., Poudel, BR., Lee, MC. 2011. Estrogen and Progesterone Receptor Expression in Breast Cancer. *Journal of Nepal*, 1(2):100-103.
- Peiris, H., Mudduwa, L., Thalagala, N., Jayatialake, K. 2017. The Value of Nottingham Grade in Breast Cancer Re-visited in the Sri Lankan Setting. *Malaysian Journal of Pathology*, 39(2):141-148
- Polyak, K. 2011. Heterogeneity in Breast Cancer. *The Journal of Clinical Investigation*, 2(10): 3786-3788.
- Prasad, S., Ravindran, J., Aggarwal, BB. 2010. NF-kappaB and Cancer: How Intimate is the Relationship. *Molecular and Cellular Biochemistry*, 336(1-2): 25-37.
- Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, JJ., Fredman, ER., Slingerland, JM. 2017. Obesity and Adverse Breast Cancer Risk and Outcome: Mechanistic Insight and Strategies for Intervention. *CA: A Cancer Journal for Clinicians*, 67(5): 378-397.
- Qureshi, A. dan Pervez, S. 2010. Allred Scoring for ER Reporting and its Impact in Clearly Distinguishing ER Negative from ER Positive Breast Cancer. *Jornal Pakistan Medical Association*, 60(5): 350-353.
- Rakha, E.A., Reis-Fulho, JS., Baehner, F., Dabbs, DJ., Decker, T., Eusebi, V., et al.. 2010. Breast Cancer Prognostic Classification in the Molecular Era: The Role of Histological Grade. *Breast Cancer Research* 12(207):1-12.
- Safitriana, Annisa, Yazid, Noor, Suprijono, Agus. 2010. Hubungan Antara Derajat Diferensiasi dengan Reseptor Esterogen pada Penderita Karsinoma Payudara Jenis Duktus Invasif. *Media Medika Muda*, 4(1): 59-62.
- Sastroasmoro, S., Ismael, S. 2010. *Dasar Dasar Metodologi Penelitian Klinis. Edisi 3*. Sagung Seto: Jakarta.
- Shah, R., Rosso, K., Nathanson, SD. 2014. Pathogenesis, Prevention, Diagnosis and Treatment of Breast Cancer. *World Journal of Clinical Oncology*, 5(3): 283-298.
- Singhai, R., Patil, VW., Jaiswal, SR., Patil, SD., Tayade, MB., Patil, AV. 2011. E-Cadherin as a Diagnostic Biomarker in Breast Cancer. *North American Journal of Medical Science*, 3(5): 227-233.
- Sofi, GN., Sofi JN., Nadeem R., Shiekh, RY., Khan FA., Sofi, AA., Bhat HA., Bhat RA. 2012. Estrogen Receptor and Progesterone Receptor Status in Breast Cancer in Relation to Age, Histological Grade, Size, of Lesion and Lymph

- Node Involvement. *Asian Pacific Journal of Cancer Prevention*, 13(10): 5047-5052.
- Soroush, A., Farshchian, N., Komasi, S., Izadi, N., Amirifard, N., Shahmohammad, A. 2016. The Role of Oral Contraceptive Pills on Increased Risk of Breast Cancer in Iranian Populations: A Meta-analysis. *Journal of Cancer Prevention*, 21(4): 294-301.
- Ivkovic-Kapid, T., Usaj, SK., Panjkovic, M., Ivanovic DD., Golubovic, M. 2007. Her2/Neu Overexpression in Invasive Ductal Breast Cancer-An Association with Other Prognostic and Predictive factor. *Arch Oncol*, 15(1-2):15-18.
- Tian, JM., Ran, B., Zhang, CL., Yan, DM., Li, XH. 2018. Estrogen and Progesterone Promote Breast Cancer Cell Proliferation by Inducing Cyclin G1 Expression. *Brazilian Journal of Medical and Biological Research*, 51(3):1-7.
- Al-Timimi, A.H. dan Yousif, NG. 2014. Immunohistochemical Determination of Estrogen and Progesterone Receptor in Breast Cancer: Pathological Correlation and Prognostic Indicator. *American Journal of Biomedicine*, 2(12): 1229-1239.
- Thiygajaran, M., Navrathan, N., Kumar, MTA., Singh, B. 2015. Correlation Between Estrogen Receptor, Progesterone Receptor, HER-2/neu Status and other Prognostic Factor in Carcinoma Breast in Indian Population. *International Surgery Journal*, 2(4):515-522.
- Tornatore, L., Thotakura, A.K., Bennet, J., Moretti, M., Franzoso, G. 2012. The Nuclear Factor Kappa B Signaling Pathway: Integrating Metabolism with Inflammation. *Trends in Cell Biology*, 22(11): 57-66.
- Yersal, O., & Barutca, S.. 2014. Biological Subtype of Breast Cancer: Prognostic and Therapeutic Implication. *World Journal of Clinical Oncology*, 5(3):412-424.